Get the Stockscreener App
4.315
2.88%
0.145
Abcellera Biologics Inc stock is traded at $4.315, with a volume of 1.22M.
It is up +2.88% in the last 24 hours and down -16.70% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$4.17
Open:
$4.13
24h Volume:
1.22M
Relative Volume:
0.20
Market Cap:
$1.29B
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-8.2981
EPS:
-0.52
Net Cash Flow:
$-121.38M
1W Performance:
-4.67%
1M Performance:
-16.70%
6M Performance:
+41.58%
1Y Performance:
+62.50%
1-Day Range:
$4.13
$4.325
1-Week Range:
$4.01
$4.81
52-Week Range:
$1.8906
$5.82
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
150 W 4TH AVENUE, VANCOUVER
Compare ABCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
4.305 | 1.40B | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.08 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.00 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.44 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
667.21 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
310.16 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Resumed | Leerink Partners | Outperform |
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
What Technical Tools Say About AbCellera Biologics Inc. RecoveryMarket Growth Summary & AI Powered Trade Plan Recommendations - newsyoung.net
ABCL.O Dives 6.75%—No News, No Signals—What’s Behind the Sharp Drop? - AInvest
AbCellera Biologics Inc. stock trend outlook and recovery pathEarnings Recap Report & Expert Approved Momentum Trade Ideas - Newser
AbCellera Biologics (ABCL) Advances Proprietary Pipeline with Promising Phase 1 Trial Results - Insider Monkey
Best data tools to analyze AbCellera Biologics Inc. stockQuarterly Portfolio Report & Real-Time Market Sentiment Reports - Newser
AbCellera Biologics Inc. stock chart pattern explained2025 Market Overview & Precise Swing Trade Entry Alerts - Newser
Why AbCellera Biologics Inc. stock attracts strong analyst attentionJuly 2025 Final Week & Expert Approved Trade Ideas - Newser
Smart tools for monitoring AbCellera Biologics Inc.’s price action2025 Top Gainers & Verified Entry Point Signals - Newser
How to build a dashboard for AbCellera Biologics Inc. stockJuly 2025 Rallies & AI Powered Market Entry Strategies - Newser
AbCellera Biologics Inc. stock outlook for YEARJuly 2025 Market Mood & AI Based Buy/Sell Signal Reports - Newser
Price momentum metrics for AbCellera Biologics Inc. explainedEarnings Overview Report & Expert Verified Movement Alerts - Newser
Ranking AbCellera Biologics Inc. among high performing stocks via tools2025 Trading Recap & Risk Controlled Swing Alerts - Newser
12 Best Healthcare Stocks to Buy Under $30 - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Raised to “Hold” at Wall Street Zen - Defense World
Detecting price anomalies in AbCellera Biologics Inc. with AI2025 Year in Review & Free High Accuracy Swing Entry Alerts - Newser
How AbCellera Biologics Inc. stock performs during market volatilityJuly 2025 Pullbacks & Stepwise Trade Signal Implementation - Newser
AbCellera Biologics Earnings Call: Clinical Progress and Financial Insights - MSN
AbCellera Biologics Inc. Bounces Off Moving Average SupportWeekly Risk Report & Consistent Profit Trading Strategies - sundaytimes.kr
Prelude Cuts Q2 Losses and Costs 13% - The Motley Fool
AbCellera Biologics stock rating maintained at Hold by Benchmark - Investing.com
AbCellera to Participate at Upcoming Investor Conferences in September 2025 - BioSpace
AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript - AOL.com
AbCellera to Present at Upcoming Investor Conferences in September - AInvest
AbCellera to Participate at Upcoming Investor Conferences in September - Business Wire
Penny Stocks to Watch for Growth: KORU Medical Systems, AbCellera Biologics, and Top 10 US Penny Stocks - AInvest
Industry Analysts Just Made A Huge Upgrade To Their AbCellera Biologics Inc. (NASDAQ:ABCL) Revenue Forecasts - uk.finance.yahoo.com
Multi factor analysis applied to AbCellera Biologics Inc.Free AI Forecast for Trending Stocks - Newser
How does AbCellera Biologics Inc. score in quality rankingsFree Market Open Stock Picks - newsyoung.net
AbCellera's Q2 2025 Earnings Call: Unpacking Contradictions in Regulatory Focus, Dosing Strategies, and Market Expansion - AInvest
Will AbCellera Biologics Inc. benefit from seasonalityRocket Stock Alert Service - mustnews.co.kr
AbCellera Biologics Advances Clinical Trials and Revenue Growth - TipRanks
AbCellera reports Q2 EPS (12c), consensus (16c) - MSN
AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Beats Revenue Estimates - MSN
AbCellera signals clinical-stage transition with first patient dosing for ABCL635 and targets mid-2026 data milestone - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Q2 2025 Earnings Call Transcript - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up Following Strong Earnings - Defense World
AbCellera Biologics 2025 Q2 Earnings Net Loss Narrows Slightly - AInvest
AbCellera Biologics Reports Q2 2025 Financial Results - The Globe and Mail
AbCellera Biologics Soars 19.34% on Q2 Revenue Surge - AInvest
AbCellera Biologics Inc. shares rise 15.80% premarket after reporting Q2 revenue beat estimates and beginning Phase 1 clinical trial for ABCL635. - AInvest
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... - Yahoo Finance
AbCellera Biologics Inc (ABCL) Q2 2025 Earnings Call Highlights: Revenue Surge and Clinical ... By GuruFocus - Investing.com Canada
AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - BioSpace
Decoding AbCellera Biologics Inc (ABCL): A Strategic SWOT Insigh - GuruFocus
AbCellera Biologics: Promising Pipeline and Strategic Focus Justify Buy Rating - TipRanks
Canadian biotech firm AbCellera Q2 revenue beats estimates - MarketScreener
AbCellera soars as revenue more than doubles estimates By Investing.com - Investing.com Australia
AbCellera soars as revenue more than doubles estimates - Investing.com
Abcellera Biologics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
AbCellera Biologics: A Turning Point in Biotech's Antibody Revolution - AInvest
AbCellera begins dosing in phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):